Maastricht, Netherlands-based Neuroplast, a biotech company developing autologous stem cell therapies for patients suffering from neurodegenerative diseases, announced that it has raised €10M in its Series B round of funding.
The round saw participation from Lumana Invest, Brightlands Venture Partners, LIOF, and the Innovation Credit from the Netherlands Enterprise Agency.